Telix at ASCO-GU 2026

Join Telix at ASCO-GU 2026, the premier global congress focused on advances in genitourinary cancer care, taking place in San Francisco, CA.

Telix’s theranostic portfolio will feature across the event with poster presentations in prostate cancer, metastatic bone pain and clear cell renal cell carcinoma.

Learn more about Telix’s presence below.

February 26 – 28, 2026

Moscone West | San Francisco, CA & Online
Presentations
Brian Mazzarella

Urology Austin

BiPASS: Phase 3 study of ⁶⁸Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer

Board P17, TPS406 | February 26

11:30 AM – 12:45 PM, 5:45 PM – 6:45 PM
Ebrahim Delpassand

Excel Diagnostics

SOLACE: A Phase 1 pharmacokinetic, dosimetry, safety, and dose optimization study for a single dose of ¹⁵³Sm-DOTMP (TLX090-Tx) to treat metastatic bone pain

Board N7, TPS271 | February 26

11:30 AM – 12:45 PM, 5:45 PM – 6:45 PM
Eric Jonasch

MD Anderson Cancer Centre

STARLITE-1: Phase 1b/2 study of combination ¹⁷⁷Lu-girentuximab (TLX250-Tx) plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC

Board J11, TPS582 | February 28

7:00 AM – 8:10 AM, 11:30 AM – 12:45 PM

Presentations